Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya...

Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III


"Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III (Nasdaq: ARYA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol “NAUT”


Nautilus Biotechnology is expected to receive $350 million in proceeds through the business combination, including a $200 million fully committed PIPE led by Perceptive Advisors and other top-tier healthcare investors


The business combination is expected to be completed in the second quarter of 2021.."

020821 Next-Gen Proteomics Company Nauti
.
Download • 322KB


Medical and Pharma Insider

A Program of FC Global Strategies LLC

383 Corona Street, Suite 589, Denver CO 80218 USA

Tel +1 303 478 4887

Website: www.medicalandpharmainsider.com

Email mail@medicalandpharmainsider.com

MedicalandPharmaInsider- (1).jpg
FC Global Strategies.png

©2021 Medical and Pharma Insider and FC Global Strategies LLC